HIGHLIGHTS

1957  Selected Articles from This Issue

REVIEW

1959  Ion Channels and Their Role in the Pathophysiology of Gliomas
Takeishi Takayasu, Kaoru Kurisu, Yoshua Esquenazi, and Leonar Y. Ballester

SMALL MOLECULE THERAPEUTICS

1970  Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
Yamini M. Ohol, Michael T. Sun, Gene Cutler, Paul R. Leger, Dennis X. Hu, Berenger Biannic, Payal Rana, Cynthia Cho, Scott Jacobson, Steve T. Wong, Jerick Sanchez, Niket Shah, Deepa Pookot, Betty Abraham, Kyle Young, Silpa Suthram, Lisa A. Marshall, Delia Bradford, Nathan Kozon, Xinping Han, Akinci Okano, Jack Maung, Christophe Colas, Jacob Schwarz, David Wustrow, Dirk G. Brockstedt, and Paul D. Kassner

Hiroshi Sootome, Akihiro Miura, Norio Masuko, Takamasa Suzuki, Yoshihiro Uto, and Hiroshi Hirai

1992  The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
Yohei Sugimoto, Yoshiki Katsumi, Tomoko Iehara, Daisuke Kaneda, Chihiro Tomoyasu, Kazukuta Ouchi, Hideki Yoshida, Mitsuji Miyachi, Shigeki Yagyu, Ken Kikuchi, Kunihiro Nishiyama, Yasumichi Kuwahara, Toshiyuki Kikuchi, Hajime Hosoi

2001  Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors
Chao Chen, Sichao Zhu, Xia Zhang, Tingting Zhou, Jing Gu, Yurong Xu, Quan Wan, Xiao Qi, Yezu Chai, Xiaorong Liu, Lukui Chen, Jie Yan, Yunfan Hua, and Fan Lin

2012  Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade
Eric T. Alexander, Kelsey Mariner, Julia Donnelly, Otto Phanstiel IV, and Susan K. Gilmour

2023  Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycythe Group Protein EZH2
Qiaqia Li, Kilia Y. Liu, Qi Peng Liu, Guangyu Wang, Weihua Jiang, Qingchu Meng, Yang Yi, Yongyong Yang, Rui Wang, Sen Zhu, Chao Li, Longxiang Wu, Dongyu Zhao, Lin Yan, Lili Zhang, Jung-Sun Kim, Xiongbing Zu, Anthony J. Kozielski, Wei Qian, Jenny C. Chang, Akash Patel, and Qi Cao

LARGE MOLECULE THERAPEUTICS

2023  Targeted Radionuclide Therapy in Patient-Derived Xenografts Using 177Lu-EB-RGD
Liang Zhao, Haojun Chen, Zhida Guo, Kaili Fu, Lanling Yao, Li Fu, Wei Xu, Xuejun Wen, Orit Jacobson, Xianzhong Zhang, Long Sun, Hua Wu, Qin Lin, and Xiaoyuan Chen

2044  Amivantamab (JNJ-6186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lanehart, Jocelyn Sendecki, Marinda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre, and Sheri L. Moores

2057  Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients
Eugene S. Bah, Rebecca A. Nace, Kah Whye Peng, Miguel Ángel Muñoz-Alia, and Stephen J. Russell
TABLE OF CONTENTS

2068 PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers

2079 Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

2089 Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies

2105 Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Amir A. Al-Khami, Sawsan Youssef, Yasmina Abdiche, Hoon-Kim Nguyen, Joyce Chou, Christopher R. Kimberlin, Sherman M. Chin, Cris Kamperschroer, Bart Jesse, Brent Kern, Natalja Budimir, Christopher P. Dillon, Allison Xu, Jerry D. Clark, Jeffrey Chou, Eugenia Kraynov, Arvind Rajpal, John C. Lin, and Shahram Salek-Ardakani

2117 Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

2126 Dual Epitope Targeting and Enhanced Hexamerization by DRS Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DRS Agonism

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

2139 High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzeann Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabricio, Andrew B. Sharabi, Shumei Kato, and Razelle Kurzrock

2146 Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Yingmiao Liu, Jing Lyu, Kirsten Bell Burdett, Alexander B. Sibley, Ace J. Hatch, Mark D. Starr, John C. Brady, Kelli Hammond, Federica Marmorino, Daniele Rossini, Richard M. Goldberg, Alfredo Falcone, Chiara Cremolini, Kouros Owzar, Anastasia Ivanova, Dominic T. Moore, Michael S. Lee, Hanna K. Sanoff, Federico Innocenti, and Andrew B. Nixon

2155 Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors
E. Gabriela Chiosean, Susan M. Perkins, R. Matthew Strotter, Anne Younger, Jennifer M. Funke, Safi G. Shahda, Noah M. Hahn, Kumar Sandrasegaran, David R. Jones, Todd C. Skaar, Bryan P. Schneider, Christopher J. Sweeney, and Daniela E. Matei

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

2163 Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy

The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma

Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy
Xiao-Min Wang, Pan Gu, Leorey Saligan, Michael Iadarola, Stanley Sau Ching Wong, Lian Kah Ti, and Chi Wai Cheung

Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Yoshisasa Kawai, Kenjiro Imada, Shusuke Akamatsu, Fan Zhang, Roland Seiler, Tetsutaro Hayashi, Jeffrey Leong, Eliana Beraldi, Neetu Saxena, Alexander Kretschmer, Htoo Zarni Oo, Alberto Contreras-Sanz, Hideyasu Matsuyama, Dong Lin, Ladan Fazli, Colin C. Collins, Alexander W. Wyatt, Peter C. Black, and Martin E. Gleave

Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis
Joy M. Gary, John K. Simmons, Jinfei Xu, Shuling Zhang, Tyler J. Peat, Nicholas Watson, Benjamin J. Gamahe, Ke Zhang, Alexander L. Kovalchuk, Aleksandra M. Michalowski, Jin-Qiu Chen, Tuddow Thaiwong, Matti Kuupel, Snehal Gaikwad, Maudeline Etienne, R. Mark Simpson, Wendy Dubois, Joseph R. Testa, and Beverly A. Mock

ABOUT THE COVER
In this issue of Molecular Cancer Therapeutics, Vijayaraghavan and colleagues outline the mechanism of an anti-EGFR/anti-cMET bispecific antibody, Amivantamab. The anti-tumor efficacy of amivantamab required the Fc-dependent trogocytosis, pictured on our cover. In trogocytosis, macrophages (shown in green) acquired fragments of opsonized tumor cell membranes (shown in orange). Read the full article on page 2044.